cholinergics and ANS

• Cardiovascular system: control of heart rate

• CTSCCCTube: https://www.youtube.com/watch?v=PJ8WsZOywgo . October 16, 2012

• • • Substance P is an important sensory neurotransmitter, probably especially important in nociception, and is found in:

      • Sensory afferent fibers

      • Dorsal root ganglia

      • Dorsal spinal cord horn

    • Other agents found in sensory neurons

      • Somatostatin

      • Vasoactive intestinal peptide (VIP)

      • Cholecystokinin (CCK)

      • Calcitonin gene-related peptide (CGRP) (found with Substance P in cardiovascular sensory nerve fibers)

    • Dorsal Spinal Cord (substantia gelatinosa) Interneurons

      • Enkephalins: Antinociceptive due to inhibition of substance P release and reduced transmission to higher centers

  • CNS and the Autonomic Nervous System

    • Spinal Cord Reflexes

      • Sweating

      • Blood pressure changes

      • Temperature-induced changes in vasomotor tone

      • Emptying of the bowels, bladder, seminal vesicles

    • Hypothalamic and Nucleus tractus solitarii

      • Integration of ANS Functions

        • Body temperature regulation

        • Emotions

        • Water balance

        • Sexual response

        • Fat/carbohydrate metabolism

        • Sleep

        • Blood pressure

        • Respiration

    • Higher Centers

      • Posterior and Lateral Hypothalamic Nuclei are associated with integration of autonomic sympathetic input

      • Midline nuclei in the region of the Tuber cinereum and anterior nuclei Nuclei are associated with integration of autonomic parasympathetic input

    • Peripheral ANS: Divisions

      • Sympathetic: (Thoracolumbar outflow)

      • Parasympathetic; (Craniosacral Outflow)

• • • Autonomic Nervous System Neurotransmitters: Summary

      • Neurotransmitter: Acetylcholine

        • All preganglionic autonomic fibers

        • Parasympatheticfibers

        • A few post-ganglionic sympathetic fibers

      • Neurotransmitter: Norepinephrine

        • Postganglionic Sympathetic Fibers

      • Neurotransmitter: Primary Afferents: Substance P and/or glutamate
        

• Comparisons between Sympathetic and Parasympathetic Nerves

  • Sympathetic system has a broader distribution, innervating effectors throughout the body

    • Sympathetic fibers show greater ramification.

    • Sympathetic preganglionic fibers may traverse through many ganglia before terminiating at its post-ganglionic cell.

      • Synaptic terminal arborization results in a single preganglionic fiber terminating on many post-ganglionic cells.

    • This anatomical characteristic is the basis for the diffuse nature of sympathic response in the human and other species.

  • Parasympathetic system is relatively limited

    • The parasympathetic system has its terminal ganglia near the end-organ.

    • Sometimes there is but a one-to-one ratio relationship between pre-and post-ganglionic fibers. The ratio between preganglionic vagal fibers and ganglion cells may be much higher, e.g. 1:8000 for Auerbach's plexus.

• Sympathetic Nervous System

  • Anatomical Outline

• • • • Cell bodies of preganglionic fibers: found in intermediolateral columns of the spinal cord (first thoracic to second or third lumbar segments

      • Preganglionic fiber axons synapse with sympathetic ganglionic neurons which lie outside the cerebrospinal axis.

      • Sympathetic ganglia are found at three sites:

        • Paravertebral

        • Prevertebral

        • Terminal

      • Paraverebral ganglia: 22 interconnected pairs on either sides of the vertebral column. (para: Gr: at the side of along side)

        • Myelinated preganglionic fibers (white rami: thoracolumbar outflow only) leave through the anterior spinal roots.

        • Postganglionic fibers (gray rami) runs back to spinal nerves for distribution to:

          • Blood vessesls of the skin

          • Blood vessels of skeletal muscle

          • Sweat glands

          • Pilomotor muscles

      • Prevertebral Ganglia: abdominal and pelvic location, comprised of:

        • Celiac ganglia

        • Superior mesenteric ganglia

        • Aorticorenal and inferior mesenteric ganglia

      • Terminal Ganglia: few, residing near the innervated organ, including

        • Ganglia associated with the urinary bladder and rectum

        • Cervical ganglia (neck): three ganglia (chain) mediating vasomotor, secretory, pupillodilatory and pilomotor responses of the head and neck)

        • All postganglionic fibers arise from cell bodies located within these ganglia; the preganglionic fibers come from upper thoracic segments: No sympathetic preganglionic fibers come from above the first thoracic level

      • Adrenal medulla is similar to sympathetic ganglia.

        • Difference:

• Usually, parasympathetic and sympathetic systems are physiological antagonists; that is, if one system facilitates or augments a process the other system inhibits the process.

• Since most visceral organs are innervated by both system, the activity of the organ is influenced by both, even though one system may be dominant.

• The general pattern of antagonism between sympathetic and parasympathetic systems is not always applicable.

  • The interaction between sympathetic and parasympathetic systems may be independent or interdependent.

    • Examples of Antagonistic Interactions between Sympathetic and Parasympathetic Systems (Examples)

      1. Actions of sympathetic and parasympathetic influences on the heart.

      2. Actions of sympathetic and parasympathetic influences on the iris.

    • Interdependent or Complementary Sympathetic and Parasympathetic Effects

      1. Actions of sympathetic and parasympathetic systems on male sexual organs are complementary.

    • Independent Effects

      1. Vascular resistance is mainly controlled by sympathetic tone.

  • Fight or Flight: General Functions of the Autonomic Nervous System

    • ANS regulates organs/processes not under conscious control including:

      1. Circulation

      2. Digestion

      3. Respiration

      4. Temperature

      5. Sweating

      6. Metabolism

      7. Some endocrine gland secretions

    • Sympathetic system is most active when the body needs to react to changes in the internal or external environment:

      1. The requirement for sympathetic activity is most critical for:

         • Temperature regulation

         • Regulation of glucose levels

         • Rapid vascular response to hemorrhage

         • Reacting to oxygen deficiency

    • During rage or fright the sympathetic system can discharge as a unit affecting multiorgan systems.

      1. Sympathetic fibers show greater ramification.

      2. Sympathetic preganglionic fibers may traverse through many ganglia before terminiating at its post-ganglionic cell. Synaptic terminal arborization results in a single preganglionic fiber terminating on many post-ganglionic cells.

      3. This anatomical characteristic is the basis for the diffuse nature of sympathic response in the human and other species.

• • • Parasympathetic responses

      1. Slows heart rate.

      2. Protects retina from excessive light.

      3. Lowers blood pressure.

      4. Empties the bowel and bladder.

      5. Increases gastrointestinal motility.

      6. Promotes absorption of nutrients.

• Neurotransmitters and the Autonomic Nervous System

  • Neurotransmitter Criteria: To support the idea that a chemical is a neurotransmitter, several conditions must be satisfied---

    • The chemical should be found in the appropriate anatomical location (e.g. synaptic terminal)

    • Enzymes that are involved in "transmitter" synthesis should also be present.

    • Where possible (as in autonomic transmission), recovery of the "transmitter" in higher quantities following nerve stimulation than in the absence of stimulation.*

    • Externally applied (e.g. iontophoretically applied) chemical produces the same effect as stimulation. For example, the reversal potential is the same.

    • Effects of antagonists influence the response to externally applied chemical in the same manner as antagonists modify responses following nerve stimulation.
      * may not be possible in many instances

  • Neurotransmission Steps

    • Axonal conduction

      • Depolarization of the axonal membrane potential results in an action potential.

      • The upstoke of the action potential is a sodium current flowing through voltage-activated sodium channels

      • As the membrane potential decreases, activation occurs of an outgoing potassium current, which opposes further depolarization and initiates repolarization.

      • Longitudinal spread of local depolarizing sodium currents results in progressive, longitudinal activation of sodium channels and new sites of depolarization. The rate of conduction is dependent on the number and synchrony of sodium channel activation.

      • Number and synchrony of sodium channel activation is membrane potential dependent.

        • As the resting membrane potential decrease (towards 0), fewer sodium channels will be activated by a depolarizing influence and conduction velocity slows.

      • In myelinated fibers, depolarization occurs at the Nodes of Ranvier.

    • Synaptic (Junctional) Activity

    • Storage and Release of Neurotransmitter

      • Small molecule neurotransmitters (e.g. acetylcholine, norepinephrine) are synthesized at axonal terminals and stored in synaptic vesicles

• "The electron micrograph shows synaptic vesicles, purified from rat brain (negative staining, courtesy of Dr. Peter R. Maycox).

  • Each is about 50 nm in diameter (1/20,000th of a millimeter).

  • The inset shows a few vesicles labeled by immunogold for one of the major synaptic vesicle proteins (synaptophysin)."--Research group of Reinhard Jahn

• "Synaptic vesicles belong to the most abundant organelles in the body.

  • The human CNS contains about 10¹¹ neurons. Each of these neuron forms on average about 1000 synapses, and each synapse contains about 500 vesicles, resulting in more than 10¹⁷ synaptic vesicles.

  • This is more than eight magnitudes more than the human genome has base pairs!

  • Synaptic vesicles can be purified in high yields to high degrees of purity, allowing for their biochemical characterization. Presently, synaptic vesicles are probably the best characterized organelles.

  • They contain a limited number of proteins that in many cases were discovered as the prototype of small protein families with a widespread distribution on trafficking organelles.

  • According to our current estimates, the majority of all vesicle-associated proteins are known.

    • The vesicle proteins can be divided into two groups according to their function: the trafficking proteins and the proteins involved in neurotransmitter uptake and storage.

      • The first group includes proteins of diverse structure such as:

        • Synaptobrevin/VAMP (involved in exocytotic membrane fusion)

        • Synaptotagmin (the exocytotic Ca²⁺-sensor)

        • Rab proteins (probably mediators of protein assembly required for membrane fusion) and

        • Several proteins of unknown function that contain four transmembrane domains (synaptophysins, synaptogyrins, SCAMPs).

      • The second group includes the neurotransmitter transporters, the vacuolar proton ATPase, and probably ion channels required for compensatory charge equilibration." ---Research group of Reinhard Jahn

• Schekman R ("Randy Schekman explains how vesicles carrying neurotransmitters dock and fuse with the nerve cell plasma membrane releasing their contents into the synapse.")

• https://www.youtube.com/watch?v=zHewifCt9Kc .

• • Isolated neurotransmitter "quanta", perhaps corresponding to single vesicle neurotransmitter quantity, is randomly released in the basal state.

    • This level of release, generating miniature end-plate potentials (mepp's), is necessary for resting skeletal muscle tone.

• Twedt R Gala R Chemical Synapse Animation

• https://www.youtube.com/watch?v=mItV4rC57kM

• • Action Potentials, promoting calcium influx, induce large, synchronous release of several hundred quanta .

    • Calcium facilitates vesicular membrane-synaptic membrane fusion, resulting in vesicular content discharge into the synaptic cleft.

• • Many chemical can inhibit norepinephrine or acetylcholine release through receptor interactions at the appropriate terminal. Examples:

    • Norepinephrine + presynaptic α₂-adrenergic receptor (autoreceptor) inhibits norepinephrine release

    • α₂ receptor antagonists increase release of norepinephrine

    • Neurally-mediated acetylcholine release from cholinergic neurons is inhibited by α₂-adrenergic receptor agonists

    • Stimulation of presynaptic β₂ adrenergic receptors increases slightly norepinephrine release

  • These agents inhibit neurally-mediated norepinephrine released by interacting with presynaptic receptors

    • Adenosine

    • Acetylcholine

    • Dopamine

    • Prostaglandins

    • Enkephalins

  • Neurotransmitter + Post-Junctional Receptors Interactions Lead to Physiological Response

    • Neurotransmitter diffuses across the synaptic cleft and bind to post-junctional receptors causing an increase in membrane conductance (ions flow)

• • • Three primary types of changes in conductance may occur:

      • Increase in Na⁺ (usually) or Ca⁺ conductance which depolarizes the membrane (EPSP)

      • Increase in Cl^- permeability: inward hyperpolarizing flow : membrane potential more negative) (IPSP)

      • Increase in K⁺ permeability; K⁺ leaves the cells, resulting in hyperpolarization, (IPSP)

  • If the EPSP is of sufficient magnitude to cause the membrane potential to reach the threshold potential, an action potential results (e.g. in skeletal or cardiac muscle). In gland cells an EPSP may cause secretion; in other cells, an EPSP may increase the rate of spontaneous depolarization.

  • An IPSP (produced in neurons and smooth, but not skeletal muscle) opposes EPSPs.

  • Definitions: EPSP: excitatory postsynaptic potential; IPSP: inhibitory postsynaptic potentia

• • Termination of Transmitter Action

    • Cholinergic: Termination of action of acetylcholine is acetylcholine hydrolysis. (acetylcholinesterase-catalazed)

      • If acetylcholinesterase is inhibited, the duration of cholinergic effect is increased.

    • Adrenergic: Termination of action of adrenergic neurotransmitters is by reuptake and diffusion away from receptors.

    • Amino Acids: Termination of action of amino-acid neurotransmitters is by active transport into neurons and glia.

  • Other Nonelectrogenic Functions

    • Basal, quantal release of transmitter in quantities insufficient to generate an EPSP may have other actions. These effects may include:

      • Regulation of neurotransmitter biosynthetic and degradative enzymes

      • Pre- and post-synaptic receptor density.

• Cholinergic Neurotransmission

  • Transmitter Synthesis and Degradation

    • Acetylcholine is synthesized from the immediate precursors acetyl coenzyme A and choline in a reaction catalyzed by choline acetyltransferase (choline acetylase).

• • Acetylcholinesterase

    • Rapid inactivation of acetylcholine is mediated by acetylcholinesterase.

    • Acetylcholinesterase is present at ganglia, visceral neuroeffector junctions, and neuromuscular junctional endplates.

    • Another type of cholinesterase, called pseudo-cholinesterase or butyrylcholinesterase has limited presence in neurons, but is present in glia. Most pseudocholinesterase activity is found in plasma and liver.

    • Pharmacological effects of anti-cholinesterase drugs are due to inhibition of acetylcholinesterase.

  • Acetylcholine Storage and Release

    • Small random release of acetylcholine-quanta, producing miniature end-plate potentials (mepps) , are released by presynaptic terminals.

      • These small currents were linked to ACh release since anticholinesterases (neostigmine) increased their effects, while cholinergic receptor antagonist (tubocurarine, a nicotinic receptor blocker) blocked.

    • Anatomical counterpart to the electrophysiological quanta is the synaptic vesicle.

    • The model is based on the nicotinic, skeletal neuromusclar junction.

    • Synchronous exocytotic release of many more quanta, dependent on Ca²⁺ occur when an action potential reaches the terminal.

    • Exocytotic release of acetylcholine and other neurotransmitters is inhibited by toxins elaborated by Clostridium botulinum.

  • Botulism

    • Botulism is caused by the most potent neurotoxins known. The neurotoxins are produced and liberated by Clostridium botulinum.

    • C. botulinum, ubiquitously found in soil and marine environments, is a group of gram positive anerobes that form spores.

• • • Eight distinct toxins have been characterized, all but one being neurotoxic.

    • Botulinum neurotoxin affects cholinergic nerve terminals:

      • Postganglionic parasympathetic endings

      • Neuromuscular junctions

      • Peripheral ganglia

      • CNS is not involved

• • • Botulinum neurotoxin prevents acetylcholine release:

      • Binds presynaptically

      • Internalized in vesicular form

      • Released into the cytoplasm

      • The toxin(s), (zinc endopeptidases) causes proteolysis of components of the neuroexocytosis system.

  • Cholinergic Transmission: Site Differences

    • Skeletal Muscle

      • Neurotransmitter: Acetylcholine

      • Receptor Type: Nicotinic

      • Sectioning and degeneration of motor and post-ganglionic nerve fibers results in:

        • Enhanced post-synaptic responsiveness, denervation hypersensitivity.

          • Denervation hypersensivity in skeletal muscle is due to

            1. Increased expression of nicotinic cholinergic receptors

            2. Spread to regions away from the endplate.

• Autonomic Effectors

• • Neurotransmitter: Acetylcholine

  • Receptor type: Muscarinic

  • Effector coupled to receptor by a G protein

  • In smooth muscle and in the cardiac conduction system, intrinsic electrical activity and mechanism activity is present, modifiable by autonomic tone.

    • Activities include propagated slow waves of depolarization: Examples: intestinal motility and spontaneous depolarizations of cardiac SA nodal pacemakers.

  • Acetylcholine decreases heart rate by decreases SA nodal pacemaker phase 4 depolarization.

    • The cardiac action potential associated with HIS-purkinje fibers or ventricular muscle consists of five phases

      • Phase 0 corresponds to Na⁺ channel activation.

        • The maximum upstroke slope of phase 0 is proportional to the sodium current.

        • Phase 0 slope is related to the conduction velocity in that the more rapid the rate of depolarization the greater the rate of impulse propagation.

      • Phase 1 corresponds to an early repolarizing K⁺ current. This current like the Phase 0 sodium current is rapidly inactivated.

      • Phase 2 is the combination of an inward, depolarizing Ca²⁺ current balanced by an outward, repolarizing K⁺ current (delayed rectifier).

      • Phase 3 is also the combination of Ca²⁺ and K⁺ currents

        • Phase 3 is repolarizing because the outward (repolarizing) K⁺ current increases while the inward (depolarizing) Ca²⁺ current is decreasing.

      • Phase 4 in normal His-Purkinje and ventricular muscle cells is characterized by a balance between outward Na+ current and inward K+ current. As a result, the membrane potential would normally be flat.

        • In disease states or for other cell types (SA nodal cells) the membrane potential drifts towards threshold.

          • This phenomenon of spontaneous depolarization is termed automaticity and has an important role in arrthymogenesis.

        • Rate of phase 4 depolarization is decreased by an increase in K⁺ conductance, which leads to membrane hyperpolarization (takes longer to reach threshold).

• Autonomic Ganglia

  • Neurotransmitter: Acetylcholine

  • Receptor type: Nicotinic

  • Generally similar to skeletal muscle site: initial depolarization is due to receptor activation.

    • The receptor is a ligand-gated channel.

• Blood vessels

  • Choline ester administration results in blood vessel dilatation as a result of effects on prejunctional inhibitory synapses of sympathetic fibers and inhibitory cholinergic (non-innervated receptors).

    • In isolated blood vessel preparations, acetycholine's vasodilator effects are mediated by activation of muscarinic receptors which cause release of nitric oxide, which produces relaxati0n

• Signal Transduction

  • Nicotinic Receptors

    • Ligand-gated ion channels

    • Agonist effects blocked by tubocurarine

    • Receptor activation results in:

      • Rapid increases of Na⁺ and Ca²⁺ conductance.

      • Depolarization

      • Excitation

    • Subtypes based on different subunit composition: muscle and neuronal classification.

  • Muscarinic Receptors

    • G-protein coupled receptor system

    • Slower responses

    • Agonist effects blocked by atropine

    • At least five receptor subtypes have been described by molecular cloning.

      • Variants have distinct anatomical locations and differing molecular specificities.

• Adrenergic Neurotransmission: Introduction to the Neurotransmitters

  • Norepinephrine: transmitter released at most postganglionic sympathetic terminals

  • Dopamine: major CNS neurotransmitter of mammalian extrapyramidal system and some mesocortical and mesolimbic neurononal pathways.

  • Epinephrine: most important hormone of the adrenal medulla

• Catecholamine Synthesis, Storage, and Release

  • Aromatic L-amino acid decarboxylase (DOPA decarboxylase)

    • Dopa leads to dopamine

    • Methyldopa leads to a-methyldopamine (converted by dopamine β hydroxylase to the "false transmitter" α-norepinephrine)

    • 5-hydroxy-L-tryptophanleads to5-hydroxytryptamine (5-HT)

  • Tyrosine Hydroxylase

    • Tyrosine leads to DOPA

    • Rate limiting step in pathway

    • Ttyrosine hydroxylase is a substrate for cAMP-dependent and Ca²⁺ - calmodulin-sensitive protein kinase and protein kinase C

    • Increased hydroxylase activity is associated with the phosphorylated enzyme

  • Catecholamine Storage

    • In adrenergically innervated tissue: norepinephrine is localized in post-ganglionic nerve terminals

      • Large dense core vesicles (corresponding to chromaffin granules)

      • Small dense core vesicles (containing norepinephrine, ATP, and membrane-bound dopamine β-hydroxylase

    • In the adrenal medulla, catecholamines are localized in chromaffin granules.

• • The most abundant catecholamine in the adrenal medulla is epinephrine.

  • The adrenal medulla has two cells types containing catecholamines:

    • One type contains mainly norepinephrine

    • The second type contains mainly epinephrine.

  • Epinephrine-containing cells express cytoplasmic phenylethanolamine-N-methyl transferase, allowing conversion of norepinephrine to epinephrine.

  • Norepinephrine:

    • Synthesized in granules

    • Diffuses out, is methylated in the cytoplasm to epinephrine

    • Then reenters the chromaffin granules.

  • About half of dopamine is formed in sympathetic neuronal cytoplasm is actively translocated into dopamine β-hydroxylase-containing vesicles, where the final step, conversion to norepinephrine occurs.

    • The remaining dopamine is converted to homovanillic acid.

  • Regulation of Adrenal Medullary Catecholamine Levels

    • An important factor controlling the rate of epinephrine synthesis and adrenal medullary epinephrine concentration is glucocorticoid concentration.

    • Glucocorticoids:

      • Are secreted by the adrenal cortex

      • Are carried by an intra-adrenal portal vascular system to the adrenal medullary chromaffin cells

      • Induce synthesis of phenylethanolamine-N-methytransferase.

      • Also increase levels of tyrosine hydroxylase and dopamine β-hydroxylase.

    • Stress leads to increased corticotropin leads to increased cortisol, increased epinephrine

• Reuptake

  • Following release from adrenergic nerve endings, termination of norepinephrine effect is mainly due to reuptake into presynaptic terminals.

  • In tissues with wide synaptic gaps and in blood vessels, the effect of released norepinephrine is ended by:

    • Enzymatic breakdown

    • Diffusion away from receptors

    • Extraneuronal uptake.

  • Neuronal norepinephrine reuptake requires two systems:

    • A transport system that translocates norepinephrine from extraneuronal spaces into cytoplasm.

    • A transport system that translocates norepinephrine from the cytoplasm into vesicles.

  • Translocation of norepinephrine from extraneuronal spaces (uptake I) into the cytoplasm is blocked by:

    • Cocaine

    • Tricyclic antidepressants (e.g. imipramine (Tofranil))

    • Imipramine (Tofranil) : Tricyclic Antidepressant

      • Inhibits norepinephrine and serotonin reuptake

      • Anticholinergic properties

      • Antihistaminic properties

      • Orthostatic hypotension due to α-receptor blockade

      • Sedation

      • Mild analgesic

    • Labeled Uses

      • Endogenous depression (an serotonin-specific reuptake inhibitor (SSRI) or other second generation agent is likely to be used first)

      • Occasionally, reactive depression

      • Treatment of enuresis in children older than six.

Shannon, M.T., Wilson, B.A., Stang, C. L. In, Govoni and Hayes 8th Edition: Drugs and Nursing Implications Appleton & Lange, 1995, pp. 616-619

• Mechamisms of Indirect Acting Sympathomimetics

• • An indirect acting sympathomimetic acts mainly by promoting norepinephrine release from nerve terminals.

  • Mechanism: These amines, all substates for uptake I, act by:

    • competing with noradrenergic vesicular transport systems, thus making norepinephine more available for release.

  • Indirect-acting agents, such as tyramine, produce tachyphylaxis in which repetitive doses of tyramine results in a progressively diminishing response.

    • Tachyphylaxis may result from depletion of a small pool of vesicular norepinphrine residing near the presynaptic membrane.

  • Uptake II is an extraneuronal (glia, heart, liver, etc )amine translocator that exhibits low affinity for norepinephrine and higher affinities for epinephrine and isoproterenol. This system is of limited physiological significance, unless Uptake I is blocked.

• Metabolic Transformation

  • Besides reuptake and diffusion away from receptor sites, catecholamine action can end due to metabolic transformation.

  • Two primary degradative enzymes:

    • Monoamine Oxidase (MAO)

    • Catechol-O-Methyl Transferase (COMT)

  • Inhibitors of MAO, such as pargyline, phenelzine (Nardil), and tranylcypromine (Parnate) increase norepinephrine, dopamine, and serotonin (5-HT) brain concentrations.

    • These concentration increases may be responsible for antidepressant action of MAO inhibitors.

  • Monoamine Oxidase Inhibitor: Phenelzine [Nardil]

    • Hydrazine MAO inhibitor with amphetamine-like activity

    • Termination of drug action requires new MAO enzyme synthesis

    • May cause Hypertensive crisis

    • Labeled Uses

      1. Rreatment of endogenous depression

      2. Management of depressive phase of bipolar disorder

      3. Treatment of severe reactive depression not responsive to other drugs.

Shannon, M.T., Wilson, B.A., Stang, C. L. In, Govoni and Hayes 8th Edition: Drugs and Nursing Implications Appleton & Lange, 1995, pp. 904-905

• Catecholamine Release (Adrenal medulla)

  • Release steps: Chromaffin Granule Adrenal medulla

    • Preganglion fiber releases Ach →nicotinic receptor activation→depolarization→Ca²⁺ entry →exocytosis of granular content

    • Ca²⁺ influx is important in excitation (depolarization)--release coupling

Lefkowitz, R.J, Hoffman, B.B and Taylor, P. Neurotransmission: The Autonomic and Somatic Motor Nervous Systems, In, Goodman and Gillman's The Pharmacologial Basis of Therapeutics,(Hardman, J.G, Limbird, L.E, Molinoff, P.B., Ruddon, R.W, and Gilman, A.G.,eds) TheMcGraw-Hill Companies, Inc.,1996, pp.112-137

• β-adrenergic receptors

  • Order of agonist potency

    • Isoproterenol > epinephrine > norepinephrine

  • β receptors are divided into two major categories: β₁ and β₂.

    • β₁ receptors → myocardium.

    • β₂ receptors → smooth muscle and most other sites.

  • The subdivision of beta receptors followed from the observation that in the heart norepinephrine and epinephrine were equipotent, whereas epinephrine was many fold (10 - 50) more potent at smooth muscle.

  • A β₃ receptor has been found that is strongly activated by norepinephrine compared to epinephrine and may explain "atypical" pharmacological properties of adipose tissue.

    • The β₃ -receptor is not blocked by propranolol, classified as a non selective beta-receptor blocker.

    • The β₃ -receptor is not blocked by propranolol, classified as a non selective beta-receptor blocker.

  • Activation of β₁, β₂ and β₃ receptors increases adenylyl cyclase activity (G_s mediated) resulting in a rise of intracellular cAMP.

    • Cardiac inotropic effects result from increases in Ca²⁺ concentration, due to:

      • phosphorylation of L-type Ca²⁺ channels

      • phosphorylation of sarcolemmal Ca²⁺ pumps

      • direct action G_s action on the L-type channel

    • Effects on the liver lead to activation of glycogen phosphorylation

  • β₂ receptor activation mediates relaxation of vascular smooth muscle

    • β₂ receptor activation mediates relaxation of G.I. smooth muscle. α₂ adrenergic receptor activation acts presynaptically to reduce Ach release and promote G.I. smooth muscle relaxation.

    • The α₂ receptor effect is the more important.

• α-Adrenergic Receptors

  • Order of agonist potency

    • epinephrine > norepinephrine >> isoproterenol

    • Multiple α receptor subtypes have been identified.

    • Multiple forms were suggested when, after administration of an α-receptor antagonist, repetitive nerve stimulation resulted in increasing amount of norepinephrine release. This findings suggested a presynaptic α-receptor binding site.

    • Post-synaptic receptors→ α₁ .

    • Pre-synaptic receptors→ α₂ .

    • α₂ receptors are also present post-synaptically. This site is involved in the action of some centrally-acting antihypertensive agents, e.g. clonidine.

    • Some drugs, such as clonidine are more active at α₂ receptors.

• Clonidine (Catapres)

  • Clonidine acts in the brain at post-synaptic α₂ receptors, inhibiting adrenergic outflow from the brainstem. Inhibition of sympathetic outflow results in a decrease in blood pressure.

  • Clonidine reduces cardiac output (by reducing both stroke volume and heart rate) and peripheral resistance. Reduction in stoke volume occurs due to increased venous pooling (decreased preload).

  • Clonidine does not interfere with cardiovascular responses to exercise.

  • Renal blood flow and function is maintained during clonidine treatment.

  • Clonidine has minimal or no effect on plasma lipids.

  • Adverse Effects

    • Dry Mouth (xerostomia)

    • Withdrawal syndrome upon abrupt discontinuation (increased blood pressure, headache, tachycardia, apprehension, tremors)

    • Bradycardia (in patients with SA nodal abnormality)

  • Some drugs such as methoxamine (Vasoxyl) or phenylephrine (Neo-Synephrine) are more active at α₁ receptors.

  • Multiple forms of both α₁ and α₂ receptors have been identified.

• Dopamine

  • D₁ receptor activation results in stimulation of adenylyl cyclase activity.

  • Smooth muscle relaxation (e.g. renal vasodilation) would result from increases in cAMP caused by activation of D₁ receptors

    • Increased cAMP levels may facilitate inactivation of myosin light chain kinase, MLK (activated by calcium-calmodulin complexes which means that increased Ca²⁺ promotes MLK activation).

    • Note that only phosphylated myosin can bind to actin and that phosphorylation state is controlled by the enzyme myosin light chain kinase.

  • D₂ receptor activation inhibits cAMP production (inhibits adenylyl cyclase activity), increases K⁺ conductance and decreases calcium influx.

• Catecholamine Refractoriness

  • Following exposure to catecholamines, there is a progressive loss of the ability of the target site to respond to catecholamines. This phenomenon is termed tachyphylaxis, desensitization or refractoriness.

  • Regulation of catecholamine responsiveness occurs at several levels:

    • Receptors

    • G proteins

    • Adenylyl cyclase

    • Cyclic nucleotide phosphodiesterase

  • Stimulation of β-adrenergic receptors rapidly causes receptor phosphorylation and decreased responsiveness. The phosphorylated receptor exhibits:

    • decreased coupling to G_s and

    • decreased stimulation of adenylyl cyclase.

• Other Autonomic Neurotransmitters/Cotransmitters

  • ATP

    • ATP and catecholamines are found together in neuronal and adrenal medullary storage granules. ATP is released along with transmitters and, in certain cases, has an important role in synaptic transmission.

  • Vasoactive Intestinal Peptide (VIP)

    • Vasoactive intestinal peptide (VIP) is found in association with ACh in autonomic parasympathetic fibers innervating blood vessels and exocrine glands and cholinergic sympathetic fibers innervating sweat glands.

    • VIP may be involved in salivation, tracheal and the GI tract responsiveness to parasympathetic input.

  • Neuropeptide Y Family

    • The neuropeptide Y family includes NPY, pancreatic polypeptide, and peptide YY.

    • NPY in the periphery is associated with sympathetic fibers and assists in maintaining vascular tone.

    • NPY is a potent, long-lasting vasoconstrictor, especially of small vessels

  • Purines

    • Purines such as ATP and adenosine may be responsible for apparent non-cholinergic, non-adrenergic autonomic neurotransmission.

  • Nitric Oxide

    • Blood vessel endothelium is required for ACh-mediated smooth muscle relaxation.

    • The endothelial cell layer modulates vessel responsiveness to autonomic and hormonal influences.

    • Endothelial cell elaborate endothelium-derived relaxing factor (EDRF, nitric oxide) and a contracting factor.

    • Pharmacological actions of serotonin, histamine, bradykinin, purines, thrombin are mediated to some degree by stimulation of EDRF release.

    • Endothelial-released nitric oxide diffuses into vascular smooth muscle and activates guanylyl cyclase which increases cGMP.

    • Clinically, hypotension associated with endotoxemia may be mediated partially by increased release of nitric oxide. A similar mechanism is proposed for hypotension induced by cytokines.

• A principal mechanism for arterial blood pressure control is the baroreceptor reflex.

• The reflex is initiated by activation of stretch receptors located in the wall of most large arteries of the chest and neck.

• A high density of baroreceptors is found in the wall of each internal carotid artery (just above the carotid bifurcation i.e. carotid sinus) and in the wall of the aortic arch.

• As pressure rises and especially for rapid increases in pressure:

  • Baroreceptor input to the tractus solitarius of the medulla results in inhibition of the vasoconstrictor center and excitation of the vagal (cholinergic) centers resulting in:

    • Vsodilatation of the veins and arterioles in the peripheral vascular beds.

Negative chronotropic and inotropic effects on the heart. (slower heart rate with reduced force of contraction)

• Transmitter Synthesis: Site 1

  • Cholinergic

    • Hemicholinium (HC-3) blocks the choline transport system into the nerve ending, thus limiting acetylcholine (ACh) synthesis.

  • Adrenergic

    • Α-methyltyrosine inhibits tyrosine hydroxylase thus preventing synthesis of norepinephrine.

• Transmitter Release: Site 2

  • Cholinergic

    • Botulinum toxin can be used clinically to treat ocular muscle spasms, muscle dystonias, and spasms.

    • Botulinus toxin binding at a presynaptic site blocks ACh release.

    • Vesamicol blocks ACh transport into storage vesicles, thus limiting release.

  • Adrenergic

    • Bretylium and guanethidine prevent action-potential mediated norepinephrine release.

    • Transient release may occur with these agents because they displace norepinephrine from storage sites.

    • Tyramine, amphetamine, and ephedrine can produce a brief liberation of transmitter.

    • Reserpine, by inhibiting vesicular uptake, produces a slow, depletion of norepinephrine, ultimately causing adrenergic blockade.

      • Cytoplasmic MAO metabolizes the neurotransmitter.

    • Reserpine similarly depletes dopamine and serotonin. Physiological effects of reserpine are due to depletion of many transmitters.

• Receptor Interactions: Site 3

  • Cholinergic

    • Tetraethylammonium, trimethaphan and hexamethonium are nicotinic ganglionic antagonists.

    • Decamethonium, a depolarizing drug, selectively causes neuromuscular blockade.

    • All classes of muscarinic receptors are blocked by atropine.

  • Adrenergic

    • Phenylephrine (Neo-Synephrine): an α₁ receptor agonist.

    • Clonidine (Catapres): an α₂ receptor agonist.

    • Prazosin (Minipress): an example of an α₁ receptor antagonist.

    • Yohimbine (Yocon): an example of an α₂ receptor antagonist.

    • Isoproterenol (Isuprel): β₁ and β₂ receptor agonist.

    • Dobutamine (Dobutrex): a relatively selective myocardial β₁ receptor agonist.

    • Terbutaline (Brethine): relatively selective β₂ receptor agonist.

    • Propranolol (Inderal): an example of a non-selective beta-adrenergic receptor blocker.

    • Metoprolol (Lopressor): an example of a relatively selective β₁ receptor antagonist.

• Termination of Transmitter Effects: Site 4

  • Cholinergic

    • Acetylcholinesterase inhibitors prevent breakdown and inactivation of acetylcholine.

      • ACh accumulation at the neuromuscular junction causes flacid paralysis.

      • ACh accumulation at postganglionic muscarinic sites results in either excessive stimulation (contraction and secretion) or inhibition (hyperpolarization), depending on the site.

      • ACh accumulation at autonomic ganglia cause increased transmission.

  • Adrenergic

    • Interference with neurotransmitter reuptake results in potentiation of catecholamine effects.

    • Cocaine and imipramine are examples of drugs that inhibit the reuptake system.

    • Monoamine oxidase (MAO) inhibitors potentiate actions of tyramine; whereas catechol-O-methyl transferase (COMT) inhibitors (pyrogallol and tropolone) only slightly increase catecholamine effects.